Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children
-
Published Date:
Oct 2006
-
Source:Emerg Infect Dis. 12(10):1548-1558.
-
Language:English
-
[PDF-461.07 KB]
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:We estimated cost-effectiveness of annually vaccinating children not at high risk with inactivated influenza vaccine (IIV) to range from US $12,000 per quality-adjusted life year (QALY) saved for children ages 6-23 months to $119,000 per QALY saved for children ages 12-17 years. For children at high risk (preexisting medical conditions) ages 6-35 months, vaccination with IIV was cost saving. For children at high risk ages 3-17 years, vaccination cost $1,000-$10,000 per QALY. Among children notat high risk ages 5-17 years, live, attenuated influenza vaccine had a similar cost-effectiveness as IIV. Risk status was more important than age in determining the economic effects of annual vaccination, and vaccination was less cost-effective as the child's age increased. Thus, routine vaccination of all children is likely less cost-effective than vaccination of all children ages 6-23 months plus all other children at high risk.
-
Subject:
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
image/jpeg 
text/plain
text/plain 
image/gif 
image/jpeg 
image/gif 
image/jpeg 
image/gif 
image/jpeg 
image/gif 
image/jpeg
No Related Documents.
Email
CDC-INFO
